Systemic Antitumor Effects of Electrochemotherapy Combined with Histoincompatible Cells Secreting Interleukin-2

Journal of Immunotherapy

Volumn 17, Issue 1, 1995, Pages 30-38

  Mir, Lluis M ^a   Roth, Claude ^b   Stéphane, Orlowski ^c   Françoise, Quintin Colonna ^d   Fradelizi, Didier ^e   Belehradek, Jean ^a   Kourilsky, Philippe ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT PASTEUR   (France)

^c CEA SACLAY   (France)

^d ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^e Hoˇpital Cochin ^*  (France)

Author keywords

Bleomycin; Electric pulses; Electrochemotherapy; Histocompatible cells; Interleukin 2

Indexed keywords

BLEOMYCIN; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER TRANSPLANTATION; ELECTROSTIMULATION THERAPY; LEWIS CARCINOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNOLOGY;

ANIMAL; BLEOMYCIN; CARCINOMA, LEWIS LUNG; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHO CELLS; COMBINED MODALITY THERAPY; EDEMA; ELECTRIC STIMULATION THERAPY; HAMSTERS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; SARCOMA, EXPERIMENTAL; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES; TRANSFECTION;

EID: 0028871192     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199501000-00004     Document Type: Article

References (33)

1. Mir LM, Orlowski S, Belehradek J Jr, Paoletti C. Electro-chemotherapy:potentiation of antitumour effect of bleomy-cin by local electric pulses. Eur J Cancer 1991;27:68-72.
2. Belehradek J Jr, Orlowski S, Poddevin B, Paoletti C, Mir LM. Electrochemotherapy of spontaneous mammary tumours in mice. Eur J Cancer 1991;27:73-6.
3. Mir LM, Belehradek M, Domenge C, et al. L’électrochimi-othérapie, un nouveau traitement antitumoral:premier essai clinique. [Electrochemotherapy, a novel antitumor treatment:first clinical trial.] C R Acad Sc (Paris) Sér III 1991;313:613-8.
4. Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J Jr, Mir LM. Electrochemotherapy, a new antitumor treatment:first clinical phase I-II trial. Cancer 1993;72:3694-700.
5. Belehradek J Jr, Orlowski S, Ramirez LH, Pron G, Poddevin B, Mir LM. Electropermeabilization of cells in tissues assessed by the qualitative and quantitative electroloading of bleomycin. Biochim Biophys Acta 1994;1190:155-63.
6. Orlowski S, Mir LM. Cell electropermeabilization:a new tool for biochemical and pharmacological studies. Biochim Biophys Acta 1993;1154:51-63.
7. Orlowski S, Belehradek J Jr, Paoletti C, Mir LM. Transient electropermeabilization of cells in culture:increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol 1988;37:4727-33.
8. Poddevin B, Orlowski S, Belehradek J Jr, Mir LM. Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture. Biochem Pharmacol 1991;42(S):67-75.
9. Mir LM, Orlowski S, Poddevin B, Belehradek J Jr. Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host’s defenses. Eur Cytokine Netw 1992;3:331-4.
10. Bubenik J, Voitenok NN, Kieler J, et al. Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol Lett 1988;19:279-82.
11. Bubenik J, Simova J, Jandlova T. Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. Immunol Lett 1990;23:287-92.
12. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-24.
13. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
14. Ley V, Langlade-Demoyen P, Kourilsky P, Larsson-Sciard E-L. Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo. Eur J Immunol 1991;21:851-4.
15. Ley V, Roth C, Langlade-Demoyen P, Larsson-Sciard E-L, Kourilsky P. A novel approach to the induction of specific cytotoxic T cells in vivo. Res Immunol 1991;141:855-63.
16. +T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 1992;149:3627-35.
17. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 1993;177:1127-34.
18. Ohe Y, Podack ER, Olsen KJ, et al. Combination effects of vaccination with IL2 and IL4 cDNA transfected cells on the induction of a therapeutic immune response against Lewis lung carcinoma cells. Int J Cancer 1993;53:432-7.
19. Porgador A, Gansbacher B, Bannerji R, et al. Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int J Cancer 1993;53:471-7.
20. Roth C, Mir LM, Cressent M, et al. Inhibition of tumor growth by histoincompatible cells expressing interleukin-2. Int Immunol 1992;4:1429-36.
21. Roth C, Mir LM, Cressent M, et al. Inhibition de la croissance tumorale induite par l’injection de cellules histo-incompatibles produisant de l’interleukine-2. [Inhibition of tumor growth induced by the injection of histo-incompatible cells expressing interleukin-2.] C R Acad Sc (Paris) Sér III 1992;314:499-504.
22. Belehradek J Jr, Barski G, Thonier M. Evolution of cell-mediated anti-tumor immunity in mice bearing a syngeneic chemically induced tumor:influence of tumor growth, surgical removal and treatment with irradiated tumor cells. Int J Cancer 1972;9:461-9.
23. Sigiura K, Stock CC. Studies in a tumour spectrum. III. The effect of phosphoramides on the growth of a variety of mouse and rat tumours. Cancer Res 1955;15:38-51.
24. Auerbach R, Morrissey LW, Sidky YA. Regional differences in the incidence and growth of mouse tumors following intradermal or subcutaneous inoculation. Cancer Res 1978;38:1739-44.
25. Ferrara P, Pecceu F, Marchese E, Vita N, Roskam W, Lup-ker J. Characterization of recombinant glycosylated human interleukin-2 produced by a recombinant plasmid transformed CHO cell line. FEBS Lett 1987;226:47-52.
26. Wilde DB, Marrack P, Kappler J, Dialynas DP, Fitch FW. Evidence implicating L3T4 in class II MHC antigen reactivity;monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines. J Immunol 1983;131:2178-83.
27. Golstein P, Goridis C, Schmitt-Verhulst A-M, et al. Lymphoid cell surface interaction structures detected using cy-tolysis-inhibiting monoclonal antibodies. Immunol Rev 1982;68:5-42.
28. Donohue JH, Lotze MT, Robb RJ, et al. In vivo administration of purified Jurkat-derived interleukin 2 in mice. Cancer Res 1984;44:1380-6.
29. +T cells by B7-transfected melanoma cells. Science 1993;259:368-70.
30. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102.
31. Porgador A, Tzehoval E, Katz A, et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental cells. Cancer Res 1992;52:3679-86.
32. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6.
33. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulo-cyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.